Seer to Participate in the Canaccord Genuity 45th Annual Growth Conference
Seer (Nasdaq: SEER), a company focused on proteomic insights, has announced its participation in the Canaccord Genuity 45th Annual Growth Conference in Boston.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Seer (Nasdaq: SEER), a company focused on proteomic insights, has announced its participation in the Canaccord Genuity 45th Annual Growth Conference in Boston. The company's management will engage in a fireside chat on August 13th at 9:00 a.m. ET.
Investors can access the presentation through a live webcast on the Investor section of Seer's website at investor.seer.bio, with an archived replay available after the event.
Details
News Market Reaction – SEER
The recorded move for SEER in the trading session of this news was +0.47%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming Canaccord Genuity 45th Annual Growth Conference in Boston, MA.
Seer’s management is scheduled to participate in a fireside chat on Wednesday, August 13th at 9:00 a.m. Eastern Time / 6:00 a.m. Pacific Time. A live webcast of the session will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the conference.
About Seer
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics—delivering insights with a scale, speed, precision, and reproducibility previously unattainable. Seer’s Proteograph Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to solve challenges conventional methods have failed to overcome. Traditional proteomic technologies have struggled with inconsistent data, limited throughput, and prohibitive complexity, but Seer’s robust and scalable workflow consistently reveals biological insights that others cannot. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information about Seer’s differentiated approach and ongoing leadership in proteomics, visit www.seer.bio.
Media Contact:
Consort Partners
pr@seer.bio
Investor Inquiries:
Carrie Mendivil
investor@seer.bio
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.